Deep and Repeated Response to Trastuzumab Deruxtecan in a Patient With Human Epidermal Growth Factor Receptor 2-Amplified Large-Cell Neuroendocrine Carcinoma With Brain Metastases: A Case Report

JCO Precis Oncol. 2023 Sep:7:e2300242. doi: 10.1200/PO.23.00242.

Authors

Sandra Algarin-Perneth¹, Riham Suleiman², Jithma P Abeykoon², Thorvardur Halfdanarson², Harry E Fuentes-Bayne², Joanne E Yi³, Tobias Peikert⁴, Patrick W McGarrah²

Affiliations

¹ Mayo Clinic, Knowledge and Evaluation Research Unit, Division of Endocrinology, Diabetes, Metabolism and Nutrition, Department of Medicine, Rochester, MN.
² Mayo Clinic, Division of Medical Oncology, Rochester, MN.
³ Mayo Clinic, Division of Anatomic Pathology, Rochester, MN.
⁴ Mayo Clinic, Division of Pulmonology and Critical Care Medicine, Rochester, MN.

PMID: 37883722
DOI: 10.1200/PO.23.00242

No abstract available

Publication types

Case Reports

MeSH terms

Brain Neoplasms* / drug therapy
Carcinoma, Neuroendocrine* / drug therapy
Carcinoma, Neuroendocrine* / genetics
Humans
Trastuzumab / therapeutic use

Substances

trastuzumab deruxtecan
ERBB2 protein, human
Trastuzumab